MX2011013427A - Modulation of systemic exposure to rifaximin. - Google Patents

Modulation of systemic exposure to rifaximin.

Info

Publication number
MX2011013427A
MX2011013427A MX2011013427A MX2011013427A MX2011013427A MX 2011013427 A MX2011013427 A MX 2011013427A MX 2011013427 A MX2011013427 A MX 2011013427A MX 2011013427 A MX2011013427 A MX 2011013427A MX 2011013427 A MX2011013427 A MX 2011013427A
Authority
MX
Mexico
Prior art keywords
rifaximin
modulation
systemic exposure
hepatic insufficiency
methods
Prior art date
Application number
MX2011013427A
Other languages
Spanish (es)
Inventor
William Forbes
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Publication of MX2011013427A publication Critical patent/MX2011013427A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

The present invention relates to the effect of hepatic insufficiency on the pharmacokinetics of rifaximin. Also provided are methods of determining an appropriate dose of rifaximin for a subject suffering from hepatic insufficiency. In addition, methods of treatment are provided subjects having or susceptible to hepatic insufficiency to be treated with rifaximin.
MX2011013427A 2009-06-15 2010-06-15 Modulation of systemic exposure to rifaximin. MX2011013427A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18725109P 2009-06-15 2009-06-15
US29769610P 2010-01-22 2010-01-22
PCT/US2010/038742 WO2010148040A1 (en) 2009-06-15 2010-06-15 Modulation of systemic exposure to rifaximin

Publications (1)

Publication Number Publication Date
MX2011013427A true MX2011013427A (en) 2012-04-20

Family

ID=43356731

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011013427A MX2011013427A (en) 2009-06-15 2010-06-15 Modulation of systemic exposure to rifaximin.

Country Status (9)

Country Link
EP (1) EP2442803A4 (en)
KR (1) KR20120030542A (en)
CN (1) CN102625701A (en)
AU (1) AU2010260089B2 (en)
CA (1) CA2765577A1 (en)
MX (1) MX2011013427A (en)
NZ (1) NZ597080A (en)
RU (1) RU2571268C2 (en)
WO (1) WO2010148040A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1698630T3 (en) 2005-03-03 2014-12-08 Alfa Wassermann Spa Novel polymorphic forms of rifaximin, methods for their preparation and their use in the medical preparations
ITBO20050123A1 (en) 2005-03-07 2005-06-06 Alfa Wassermann Spa GASTRORESISTIC PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMINA
WO2021152587A1 (en) 2020-01-30 2021-08-05 Yeda Research And Development Co. Ltd. Treating acute liver disease with tlr-mik inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2798253T3 (en) * 2007-07-06 2020-12-10 Lupin Ltd Rifaximin Pharmaceutical Compositions
AU2008273699A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
JP6037615B2 (en) * 2008-10-02 2016-12-07 サリックス ファーマシューティカルズ リミテッド How to treat hepatic encephalopathy
US20110035232A1 (en) * 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
RU2540513C2 (en) * 2009-06-02 2015-02-10 Саликс Фармасьютикалз, Лтд. Method of treating hepatic encephalopathy

Also Published As

Publication number Publication date
AU2010260089A1 (en) 2012-01-19
AU2010260089B2 (en) 2015-05-14
RU2571268C2 (en) 2015-12-20
EP2442803A1 (en) 2012-04-25
KR20120030542A (en) 2012-03-28
RU2012101310A (en) 2013-07-27
CN102625701A (en) 2012-08-01
EP2442803A4 (en) 2012-11-28
CA2765577A1 (en) 2010-12-23
WO2010148040A1 (en) 2010-12-23
NZ597080A (en) 2014-02-28

Similar Documents

Publication Publication Date Title
GB201601076D0 (en) Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
EA201171367A1 (en) VINYLINDASOLYL COMPOUNDS
GB201411074D0 (en) Combination treatment (e.g.with ABT-072 or ABT-333) of DAAs for use in treating HCV
MX2014011134A (en) Carbamate compounds and of making and using same.
MX2009010899A (en) Predicting post-treatment survival in cancer patients with micrornas.
IL247324A0 (en) Microrna patterns for the diagnosis, prognosis and treatment of melanoma
EA201070673A1 (en) SAFE INITIAL DOWNLOAD BY METHOD OF OPTIONAL COMPONENTS
HK1149322A1 (en) Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
EA201492187A1 (en) METHODS OF TREATMENT OF SOLID TUMORS USING COFERMENT Q10
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
EP2580580A4 (en) Integrated carbon electrode chips for the electric excitation of lanthanide chelates, and analytical methods using these chips.
EP2882447A4 (en) Methods for diagnosing, prognosing and treating muscular dystrophy
HK1212218A1 (en) Organoarsenic compounds and methods for the treatment of cancer
HK1218857A1 (en) 3, 3, 4, 4 -tetrahydroxy-2, 2 -bipyridine-n, n-dioxides for the treatment of renal cell carcinoma 3344--22--nn-
MX2011013427A (en) Modulation of systemic exposure to rifaximin.
PL2446276T3 (en) Methods for determining the oncogenic condition of cell, uses thereof, and methods for treating cancer
EP2349446A4 (en) Methods and apparatus for charging and evacuating diffusion dressing
EP2601530A4 (en) Compositions and methods for detecting, diagnosing, and treating cancer
WO2012153253A3 (en) Aromatic compounds and metal complexes thereof
IL211641A0 (en) 1-amino-alkylcyclohexane derivatives for the treatment of cognitive impairment in tinnitus
AU324728S (en) Automobile tyre
IL238536A0 (en) 6-oxo-1,6-dihydro=pyridazine derivatives for the use for the treatment of hepatocellular carcinoma
TN2015000056A1 (en) Methods of improving long-term survival and reducing hospitalization readmission rates for subjects suffering from hepatic encephalopathy
WO2014009738A3 (en) Treatment of muscular dystrophy
IL210692A0 (en) Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrobotic treatment